NCT02361723View on ClinicalTrials.gov

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

July 3, 2014

Primary Completion Date

September 3, 2019

Study Completion Date

September 3, 2019

Conditions

For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

Interventions

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

DRUG

BGB-290

Trial Locations (7)

2250

Gosford Hospital, Gosford

2500

Cancer Care Wollongong, Wollongong

3000

Peter Maccallum Cancer Centre, Melbourne

3004

Nucleus Network, Melbourne

3084

Austin Health, Heidelberg

5042

Flinders Medical Centre, Bedford PK

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BeiGene

INDUSTRY

NCT02361723 - Phase 1a/1b BGB-290 for Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter